


Transdermal Controlled Systemic Medications



edited by
Yie W. Chien

Transdermal Controlled Systemic Medications

edited by

YIE W. CHIEN

*Controlled Drug-Delivery Research Center
Rutgers-The State University
of New Jersey
Piscataway, New Jersey*



Y2000498

MARCEL DEKKER, INC.

New York and Basel

Contents

<i>Preface</i>	iii
<i>Contributors</i>	v
1. Advances in Transdermal Systemic Medication	1
<i>Yie W. Chien</i>	
I. Introduction	1
II. The Skin: Site of Transdermal Drug Administration	2
III. Early Development of Transdermal Drug Delivery	6
IV. Recent Developments in Transdermal Drug Delivery	14
References	21
DEVELOPMENT AND PRECLINICAL ASSESSMENTS OF TRANSDERMAL THERAPEUTIC SYSTEMS	
2. Developmental Concepts and Practice in Transdermal Therapeutic Systems	25
<i>Yie W. Chien</i>	
I. Introduction	25
II. Fundamentals of Rate-Controlled Transdermal Drug Delivery	26
III. Approaches to the Development of Transdermal Therapeutic Systems	31
IV. Kinetic Evaluations of Transdermal Therapeutic Systems	44
V. Formulation Design and Optimization	56
	<i>xi</i>

VI.	Enhancement of Transdermal Controlled Drug Delivery	59
VII.	Generic Program for Transdermal Drug Delivery System Development	75
	References	77
3.	Alterations in Skin Permeability	83
	<i>Eugene R. Cooper</i>	
I.	Introduction	83
II.	Enhancement Recognition	84
III.	Membrane Alterations	86
IV.	Reduction of Penetration	90
V.	Summary	90
	References	90
4.	Pressure-Sensitive Adhesives: Science and Engineering	93
	<i>Martin C. Musolf</i>	
I.	Introduction	93
II.	Pressure-Sensitive Adhesives	96
III.	Pressure-Sensitive Adhesives for Transdermal Applications	104
IV.	Summary	111
	References	112
5.	Polymeric Materials: Assessment of Skin Biocompatibility	113
	<i>Kevin S. Weadock, James M. Pachence, Richard A. Berg, and Frederick H. Silver</i>	
I.	Introduction	113
II.	Biocompatibility Testing of Polymers	114
III.	Cellular Response to Polymers	117
IV.	Polymer Degradation	118
V.	Conclusions	120
	References	120
6.	Design and Calibration of In Vitro Permeation Apparatus	127
	<i>Kakuji Tojo</i>	
I.	Introduction	127
II.	Design of In Vitro Skin Permeation Apparatus	129
III.	Method for Characterizing the Hydrodynamics of In Vitro Systems	137
IV.	Correlation Equation for Mass Transfer Coefficient	141

V.	Effect of the Diffusion Boundary Layer on Drug Permeation	143
VI.	Calculation of Intrinsic Rate of Permeation	151
VII.	Effect of Temperature on Drug Permeation	154
VIII.	Conclusion	156
	References	157
7.	In Vitro Evaluations of Transdermal Drug Delivery	159
	<i>Yih-Chain Huang</i>	
I.	Introduction	159
II.	In Vitro Skin Permeation Kinetics	160
III.	Conclusion	177
	References	177
8.	In Vivo Evaluations of Transdermal Drug Delivery	179
	<i>Richard H. Guy, Jonathan Hadgraft, Robert S. Hinz, Kathleen V. Roskos, and Daniel A. W. Bucks</i>	
I.	Introduction	179
II.	Animal Models	181
III.	Human Experimentation	192
IV.	Kinetic Modeling of Transdermal Drug Delivery	204
V.	Summary	215
	References	216
CLINICAL ASSESSMENTS OF TRANSDERMAL THERAPEUTIC SYSTEMS		
9.	Transdermal Delivery of Nitroglycerin I	227
	<i>Nathaniel Reichek</i>	
I.	Introduction	227
II.	History of Transdermal Nitroglycerin	228
III.	Problems in Assessment of Long-Acting Nitrates for Angina Prophylaxis	229
IV.	Antianginal Effect of Nitroglycerin Ointment	231
V.	Antianginal Effect of Nitroglycerin Patches	233
VI.	Attenuation of Antianginal Effects of Other Nitrates	238
VII.	Studies in Progress	240
VIII.	Future Directions	241
IX.	Conclusions	241
	References	242

10. Transdermal Delivery of Nitroglycerin II	245
<i>Dženana E. Rezaković</i>	
I. Introduction	245
II. Clinical Trials of Nitroglycerin Patches in Coronary Artery Disease	246
III. Hemodynamic Trials of Nitroglycerin Patches	284
IV. Multicenter Studies of the Nitroglycerin Patch in Europe	295
V. Old and New Data About Nitroglycerin Patch Efficacy	301
VI. Conclusions	309
References	311
11. Transdermal Delivery of Clonidine	321
<i>G. S. Perlmutter, Ester Paran, Bonita Falkner, Carol M. Bies, T. Fagan, Robert R. Chase, and David T. Lowenthal</i>	
I. Introduction	321
II. Mechanism of Action	322
III. Pharmacokinetics	322
IV. Pharmacological Effects	323
V. Adverse Effects	326
VI. Conclusions	329
References	330
12. Transdermal Delivery of Bupranolol	333
<i>Inge Weiss, Hans-Michael Wolff, Günter Cordes, and Willi Cawello</i>	
I. Introduction	333
II. Transdermal Absorption of Bupranolol in Rabbits	334
III. Pharmacokinetic and Pharmacodynamic Studies in Human Volunteers	339
IV. Evaluation of Pharmacodynamic Effects Compared to Peroral Propranolol	343
V. Summary	345
References	345

ENGINEERING AND MANUFACTURING OF TRANSDERMAL THERAPEUTIC SYSTEMS

13. Development of Processes and Equipment for Rate-Controlled Transdermal Therapeutic Systems	349
<i>John W. Dohner</i>	
I. Introduction	349
II. Transdermal Products Developed at Alza	349

III. Manufacturing Processes and Equipment	351
IV. Engineering Development of Transdermal Systems	354
V. Commercial Production of Transdermal Systems	362
VI. Summary	363
References	364
 14. Development of Processes and Technology for Adhesive-Type Transdermal Therapeutic Systems	 365
<i>Hans-Michael Wolff, Hans Rainer Hoffmann, and Günter Cordes</i>	
I. Introduction	365
II. Galenical Structure of the Deponit System	366
III. Manufacturing Process	368
IV. Comments on Galenical Design	373
References	378
 15. Product Development and Technology Transfer for Transdermal Therapeutic Systems	 379
<i>David J. Bova, Valerie N. Ahmuty, Robert L. Cirrito, Karen O'Toole Holmes, K. Kasper, Caroline LaPrade, R. LaPrade, Gustav A. Maag, Juan A. Mantelle, John A. McCarty, J. Miranda, Frankie A. Morton, and Steven Sablotsky</i>	
I. Introduction	379
II. Research Phase	380
III. Product Development and Technology Transfer	381
IV. Conclusion	396
 REGULATORY REQUIREMENTS AMONG INTERNATIONAL HEALTH AUTHORITIES	
 16. Regulatory Considerations in Transdermal Drug Delivery Systems in the United States	 399
<i>Vinod P. Shah and Jerome P. Skelly</i>	
I. Introduction	399
II. Biopharmaceutic Considerations	401
III. Regulatory Requirements	408
IV. Generic Versions of Transdermal Drug Products	410
 17. Regulatory Approval of Transdermal Therapeutic Systems in the United Kingdom	 411
<i>Paul Adams</i>	
I. Introduction	411
II. Product License Applications	412

III. Abridged Applications	412
IV. Conclusion	417
 18. Regulatory Approval of Transdermal Therapeutic Systems in Japan	 419
<i>Tsuneji Nagai and Yoshiharu Machida</i>	
I. Introduction	419
II. Application Requirements for Approval of New Prescription Drugs in Japan	420
III. Scientific Data Required for Approval of Transdermal Therapeutic Systems	423
IV. Procedure and Time Needed for Approval	429
V. Regulatory Policy in Other Asian Countries	429
Reference	430
 Index	 431

Advances in Transdermal Systemic Medication

YIE W. CHIEN / *Rutgers—The State University of New Jersey,
Piscataway, New Jersey*

I. INTRODUCTION

Continuous intravenous administration at a programmed rate of infusion has been recognized as a superior mode of drug delivery not only to bypass hepatic "first-pass" elimination, but also to maintain a constant, prolonged, and therapeutically effective drug level in the body. A closely monitored intravenous infusion can provide the advantages of direct entry of drug into the systemic circulation and control of circulating drug levels. However, this mode of drug delivery entails certain risks and, therefore, necessitates hospitalization of the patients and close medical supervision of the medication.

Recently, there has been a growing recognition that the benefits of intravenous drug infusion can be closely duplicated, without its hazards, by using the intact skin as the port of drug administration to provide continuous transdermal drug delivery into the systemic circulation (1).

Several transdermal therapeutic systems have recently been developed for topical application on the intact skin surface aiming to achieve systemic medication. This approach was exemplified first by the development of scopolamine-releasing transdermal therapeutic system (Transderm-Scop by Ciba) for 72-hr prophylaxis or treatment of motion-induced nausea (2), and then by the successful marketing

of several nitroglycerin-releasing transdermal therapeutic systems (Deponit by Pharma-Schwarz/Lohmann, Nitrodisc by Searle, Nitro-Dur by Key, and Transderm-Nitro by Ciba), as well as an isosorbide dinitrate-releasing transdermal therapeutic system (Frاندol tape by Toaeiyo, Yamanouchi) for once-a-day medication of angina pectoris (3,4), and most recently by the regulatory approval of a clonidine-releasing transdermal therapeutic system (Catapres-TTS by Boehringer Ingelheim) for weekly treatment of hypertension (4).

The intensity of interest in the potential biomedical applications of rate-controlled transdermal drug administration is further demonstrated by a substantial increase in research and development activities in many health care institutions aiming to develop patentable transdermal therapeutic systems to provide a continuous transdermal infusion of therapeutic agents for prolonged periods of time. The drug candidates evaluated have ranged from antihypertensive, antianginal, antihistamine, and anti-inflammatory agents to analgesic, antiarthritic, steroidal, and contraceptive drugs.

This chapter discusses the logic behind the concept of using intact skin as the port for continuous drug infusion as well as the historic perspective and advances in the development of rate-controlled transdermal therapeutic systems.

II. THE SKIN: SITE OF TRANSDERMAL DRUG ADMINISTRATION

The skin of an average adult body covers a surface area of approximately 2 square meters and receives about one-third of the blood circulating through the body (5). It is one of the most readily accessible organs of the human body. With a thickness of only a few millimeters (2.97 ± 0.28 mm), the skin separates the vital organs from the outside environment, serves as a protective barrier against physical, chemical or microbial attacks, acts as a thermostat in maintaining body temperature, plays a role in the regulation of the blood pressure, and protects the human body against the penetration of ultraviolet rays.

Microscopically, the skin is a multilayered organ composed of many histological layers. It is generally described in terms of three major multilaminar layers: the epidermis, the dermis, and the hypodermis (Fig. 1). The epidermis is further divided into five anatomical layers with the outermost layer of stratum corneum exposed to the external environment.

The stratum corneum consists of many layers of compacted, flattened, dehydrated, and keratinized cells. These cells are physiologically rather inactive and are continuously shed with constant




Figure 1 A cross-sectional view of human skin, showing various skin tissue layers and appendages. (From Ref. 6.)

replacement from the underlying viable epidermal tissue (6). The stratum corneum has a water content of only 20% as compared to the normal physiological level of 70%, such as in the physiologically active stratum germinativum (which is the regenerative layer of the epidermis).

The human skin surface is known to contain, on the average, 10–70 hair follicles and 200–250 sweat ducts on every square centimeter of skin area. These skin appendages, however, actually occupy, grossly, only 0.1% of the total human skin surface. Even though foreign agents, especially water-soluble ones, may be able to penetrate the skin via these skin appendages faster than through the intact area of the stratum corneum, this transappendageal route of percutaneous absorption has provided a very limited contribution to the overall kinetic profile of transdermal permeation. Therefore, the transdermal permeation of most neutral molecules at steady state can be considered as, primarily, a process of passive diffusion through the intact stratum corneum in the interfollicular region. So, for a fundamental understanding of transdermal drug infusion (7), the organization of the skin can be represented by a simplified multi-layer model as shown in Figure 2.

For many decades, the skin has been commonly used as the site for the administration of dermatological drugs to achieve localized pharmacological action in the skin tissues. In such cases, the drug molecules are considered to diffuse to a target tissue in the proximity of drug application to produce their therapeutic effect before




Figure 2 A simplified model of the human skin for mechanistic analysis of skin permeation. (From Ref. 7.)




Figure 3 Schematic illustration of drug release and absorption across the skin tissues for localized therapeutic action in the tissues directly underneath the site of drug administration or for systemic medication in the tissues remote from the site of topical drug application. (From Ref. 7.)

being distributed to the blood circulation for elimination (Fig. 3). The use of hydrocortisone for dermatitis, benzoyl peroxide for acne, and neomycin for superficial infection (8) are the few examples of application.

As discussed earlier, there is increasing recognition that the skin can also serve as the port of administration for systemically active drugs (Fig. 3). In this case, the drug applied topically will be absorbed first into the blood circulation and then will be transported to target tissues, which could be rather remote from the site of drug application, to achieve its therapeutic purposes. Examples include the transdermal controlled delivery of nitroglycerin to the myocardium for the treatment of angina pectoris, of scopolamine to the vomiting center for the prevention of motion-induced

sickness, and of estradiol to various estradiol-receptor sites for the medication of postmenopausal syndromes (9-11).

III. EARLY DEVELOPMENT OF TRANSDERMAL DRUG DELIVERY

The potential of using the intact skin as the port of drug administration to the human body has been recognized for several decades, as evidenced by the development of medicated plasters for administering medication through the skin to the underlying areas. By definition, the plaster is also a drug delivery system designed for external application. It is made of adhesive material and with proper balance of cohesive strengths, the adhesive is bonded to the backing support (Fig. 4). Such a proper balance also provides good bonding to the skin when a plaster is applied and permits a clean break from the skin surface when the plaster is removed. Historically, the medicated plaster can be viewed as the first development of the idea of transdermal drug delivery. It affords protection and support by its occlusive action, and it brings medication into close contact with the skin (12).

Little is known of the historical development of medicated plasters. However, their use can be traced back at least several hundred years to ancient China. Two representative Chinese medicated plasters, which are still available for medical practice in China, are shown in Figures 5 and 6. As indicated in Tables 1 and 2, these early generations of medicated plasters tend to contain multiple ingredients of herbal drugs and are intended for localized action in the tissues directly underneath the site of application (Fig. 7).

The medicated plaster is also very popular in Japan in over-the-counter pharmaceutical dosage forms and it is also called cataplasm (13). Salonpas is a typical example (Fig. 8). Although still composed of multiple ingredients, including six therapeutically effective agents (Table 3), the formulation has been so improved that Salonpas




Figure 4 Cross-sectional view of a medicated plaster, showing various major structural components.




Figure 5 The Yang-Cheng medicated plaster, manufactured by the United Pharmaceutical Manufactory, Kwangchow, China, used on bruises and for its analgesic properties.




Figure 6 The Shang-Shi Bao Zhen Gao medicated plaster, manufactured by Shanghai Chinese Medicine Works, Shanghai, used for rheumatoid arthritis.

Table 1 Chinese Medicated Plaster for Bruises and as Analgesic

Main ingredients	Content (%)
Fossilia ossis mastodi	10.42
Eupolyphagasinsensis walker	10.42
Sanguis draconis	4.17
Catechu	6.25
Myrrha	6.25
Rhizoma drynariae	4.17
Radix dipsaci	4.17
Flos carthami	9.17
Rhizoma rhei	8.33
Herba taraxaci	8.33
Mentholum	20.00
Methylis salicylas	8.32

Description and action: This plaster is prepared according to the dialectic therapeutics of traditional Chinese medicine. The elements of the various drugs and herbs, when applied to the skin, will penetrate into the subcutaneous tissues to stimulate circulation and produce a local analgesic effect. This plaster helps to cure inflammation of muscles and to promote the healing of bone fractures.

Indications: Bruises

Fractures

Sprains

Swelling and pains

Bad circulation of blood

Injuries and wounds

Rheumatic arthritis

Neuralgia

Limb languor

Directions: Cut a piece of desired size from the roll, remove the cellophane and apply to the affected part.

Medicinal effect lasts 24 hr.